· Total gross amount to be raised : 8,7 million euros
· transaction over-subscribed of 155%
· Implementation of the extension clause
Paris, July 19, 2013 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and supportive care products, announces a successful capital increase, with maintenance of preferential subscription rights, launched on July 2, 2013, and which will enable the Company to raise €8.74 million, after implementation of the extension clause.
“The great success of our capital increase achieved in a tough market environment represents an important vote of confidence by our shareholders, and especially Financière de la Montagne and IDInvest, who have provided significant support to BioAlliance Pharma in this transaction” comments Judith Greciet, CEO of BioAlliance Pharma. “We would like to thank them and all of the shareholders and investors who have subscribed to this transaction.”
The amount raised will enable BioAlliance Pharma to accelerate two major clinical trials in its oncology products portfolio:
- Validive®: opening of an important number of investigator center in the phase II trial in Europe and especially in the United States over the next few weeks, and
- Livatag®: extension of phase III trial to centers in Europe and quickly to centers in the United States.
“These two drugs’ development progress represents key value drivers for BioAlliance Pharma” adds Judith Greciet. “Thanks to this financing, we can expand the number of investigator centers involved in both studies, increase patient recruitment and optimize development timelines of Validive, which should complete phase II in 2014, and of Livatag.”
Details of the capital increase
The subscription period was from the July 2 to 12, 2013.
The total request has reached 3,52 millions of shares for a global amount of 12,3 millions euros, representing a subscription rate of 155%. The Chief Executive Officer has decided to fully implement the extension clause, thereby bringing the number of offered shares from 2.269.964 to 2.496.960
The gross amount of the capital increase, which has been oversubscribed, is 8.739.360 euros and implies the creation of 2.496.960 new shares after the implementation of the extension clause.
1.862.653 new shares have been subscribed on an irreducible basis, representing around 75% of new shares to be issued after exercice of the extension clause. The demand on a reducible basis accounted for 1.656.467 new shares and thus will be partially allocated up to 634.307 new shares.
The share capital will thus be increased from €4.539.928,75 to €5 164 168,75 divided into 20 656 675 shares at €0.25 nominal value per share.
The settlement and delivery of the new shares will occur on July 24, 2013 and 2.496.960 new shares will be listed on NYSE Euronext Paris on July 25, 2013 on the same listing line as the existing shares of the company (FR0010095596).
Partner of the transaction
BioAlliance Pharma thanks Invest Securities in this capital increase transaction.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 countries (EU, US, Korea), commercialized in Europe and in the US.
Sitavig® (Acyclovir Lauriad®) (labialis herpes): Registered in the US and in 8 European countries, registration status in the other European countries.
Fentanyl Lauriad® (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going
Validive® (Clonidine Lauriad®) (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA ALIZE RP
Judith Greciet, CEO Caroline Carmagnol
Tel.: +33 1 45 58 76 00 +33 6 64 18 99 59
Nicolas Fellmann, CFO Christian Berg
Tel.: +33 1 45 58 71 00 +33 6 31 13 76 20
|ONXEO||Euronext Paris||1.89 (c)||8.00%||1 626 625|